My watch list  


Systematic (IUPAC) name
CAS number 162635-04-3
ATC code  ?
PubChem 6918289
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007.[1] It is a derivative of the macrolide sirolimus.

The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).[2] The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Torisel". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE